GLP-1 Side Effects Patients Are Often Surprised By — and How They’re Managed

By Dr. Don Gates, MD, Founder of Scale Solutions

Most people starting a GLP-1 medication are told about nausea. Fewer are told that their skin might feel strange, that hair shedding usually peaks months after it starts and then stops, or that tirzepatide carries a birth control instruction that repeats every time the dose goes up.

None of that is hidden. It is all in the FDA prescribing information. But an appointment is short, the list of possible reactions is long, and clinicians naturally lead with the effects that send people to urgent care — so patients meet a side effect three weeks in with no idea whether it is expected.

Knowing about these in advance is what makes them manageable rather than alarming. Below is what current labels and trials show: which effects settle with time, which respond to a change in pacing or dose, and which are worth a call the same day.

Key Takeaways

• Dysesthesia — altered skin sensation — is real and dose-related. In trials it occurred in 22% of patients on semaglutide 7.2 mg, 6% on 2.4 mg, and 0.3% on placebo. FDA notes it generally resolved on its own or with a dose reduction.
• Constipation is more common than most patient education implies — 24% on Wegovy 2.4 mg versus 11% on placebo — and it responds well to simple, unglamorous measures.
• Hair shedding is usually a consequence of rapid weight loss, not a direct drug toxicity, and typically resolves once weight stabilizes.
• Tirzepatide’s oral contraceptive instruction repeats at every dose escalation, not just at the start. Semaglutide labels do not carry this instruction.
• A small number of symptoms are not “wait and see”: severe persistent abdominal pain, right-upper-abdominal pain after meals, persistent vomiting with signs of dehydration, or an allergic reaction all warrant prompt medical attention.

Label information and rates on this page verified August 19, 2026 against current FDA prescribing information.

Which GLP-1 Side Effects Actually Surprise People?

Nausea is well publicized and patients expect it — it occurred in 44% of patients on Wegovy 2.4 mg versus 16% on placebo. What catches people off guard are the effects further down the label: altered skin sensation, constipation, taste changes, hair shedding, fatigue, gallbladder symptoms, sulfur-smelling burps, interactions with other medications, and changes in how alcohol feels.

Two caveats before the list. These rates come from trials of specific drugs at specific doses — they are not interchangeable across medications, and a population rate is not a prediction about you. And a reaction appearing in a label does not mean the drug caused it in every case; some, hair shedding especially, are consequences of losing weight quickly by any means.

Dysesthesia: When Your Skin Feels Strange

What it is: Dysesthesia means an abnormal, often unpleasant sensation in the skin that is not explained by an injury to that area. Patients describe it as burning, tingling, prickling, a sunburn-like tenderness, or skin that feels oddly sensitive to clothing or touch. It is not a rash — there is usually nothing to see.

The Wegovy prescribing information (rev. 06/2026) states:

“Dysesthesia, and related events of altered skin sensations including paresthesia, pain of skin, sensitive skin, and burning skin sensation, occurred in clinical trials with WEGOVY injection and tablet. The incidence of dysesthesia with WEGOVY increased with increasing dosage and drug levels in the blood.”

The rates: 22% with semaglutide 7.2 mg injection, 6% with 2.4 mg injection, and 0.3% with placebo. With the 25 mg tablet, about 5% of treated patients versus none on placebo. The pattern is clearly dose- and blood-level-dependent. A similar signal has appeared with retatrutide, an investigational triple agonist that is not FDA approved and not available by prescription — 12.5% at the 12 mg dose versus 0.9% on placebo in Phase 3.

How it is managed: This is the effect most likely to frighten someone who has never heard of it, because odd skin sensations sound neurological. FDA has noted it generally resolved on its own or with dose reduction. Because it tracks with dose and drug level, the usual approach is a conversation about pacing — holding at the current dose longer, or stepping back to one that was comfortable. That is a decision to make with your clinician, not alone. New or persistent numbness or weakness should always be evaluated rather than assumed to be the medication, because other conditions cause the same symptoms.

Constipation: The Effect That Gets Overshadowed

Constipation is arguably under-discussed relative to how often it happens, because nausea dominates the conversation.

Cross-trial comparison is unreliable — these studies enrolled different populations over different durations and were never run head-to-head.

The mechanism is straightforward and doubled: these medications slow gastric emptying and gut motility, and people eating substantially less also take in less fluid and less fiber.

Management is genuinely effective here and mostly non-pharmacologic: deliberate fluid intake (appetite suppression blunts thirst cues as well as hunger cues), fiber from food where tolerated, and regular movement. Fiber supplements and osmotic laxatives are commonly used, but which is appropriate depends on your other medications and history — worth asking rather than guessing.

Constipation that is severe, or comes with abdominal pain, vomiting, or an inability to pass gas, is a different situation and should be evaluated.

Taste Changes and Food Aversions

Many patients report that foods they used to enjoy taste metallic, flat, or actively unpleasant — coffee, red meat, and greasy foods come up repeatedly.

Be careful with the numbers here. Formally reported dysgeusia (distorted taste) in the Wegovy trials was uncommon — 1.7% versus 0.5% on placebo — yet patient-reported taste and preference changes come up far more often than that suggests. The two are measuring different things: a label captures what an investigator coded as an adverse event, not every shift in appetite or preference.

How it is managed: by working around it rather than fighting it. If protein sources you relied on have become unappealing, the goal is finding ones you can tolerate — not eating less protein, which leads directly to the next section.

Hair Shedding: Common, Usually Temporary, Usually Not the Drug Itself

Direct answer: hair shedding on a GLP-1 is most often telogen effluvium — a temporary shift of hair follicles into their shedding phase, triggered by rapid weight loss and the metabolic stress that goes with it. It is well documented after rapid weight loss from any cause, including dieting and bariatric surgery. It typically resolves once weight stabilizes.

Labeled rates:

For orforglipron, Lilly reports the effect was concentrated in women (7.0% versus 0.9% in men on drug; 3.0% versus 0.7% on placebo) and states these events were associated with weight reduction rather than a direct drug effect.

Practically: shedding usually begins a couple of months after rapid loss starts, peaks, then stops. It is a delayed response to something that already happened, which is why it can feel like it is worsening just as weight loss is going well. It does not typically cause permanent hair loss.

Worth checking rather than waiting out: protein intake, plus iron, ferritin, vitamin D, and thyroid function — deficiencies and thyroid disorders cause hair loss independently and are easy to miss if everything is blamed on the medication. Shedding that is severe, patchy, or persists after weight stabilizes deserves evaluation.

Related: hair shedding on GLP-1 medications.

Fatigue — and the Under-Eating Behind It

Fatigue was reported in 11% of Wegovy 2.4 mg patients versus 5% on placebo, and in 5–7% of Zepbound patients versus 3%.

Some of this is the medication. A meaningful portion is simply that appetite suppression works — people end up eating far too little, and specifically too little protein, without noticing, because they are not hungry.

The 2026 American Diabetes Association Standards of Care in Overweight and Obesity addresses this directly. Recommendation 2.19 advises clinicians to counsel and monitor people on obesity medications “to ensure adequate nutritional intake, with particular attention to preventing protein insufficiency and micronutrient deficiencies during the active phase of weight reduction.” Recommendation 2.20 advises counseling on adequate protein intake and muscle-strengthening activities to minimize weight-loss muscle loss — both graded A, the strongest evidence level.

The guideline’s targets: a minimum of 60 g of protein daily, with 1.2–1.6 g/kg per day often advised during active weight reduction, alongside muscle-strengthening activity.

Persistent fatigue is also a reason to look beyond diet. Dehydration, anemia, thyroid disease, sleep apnea, and low B12 or vitamin D all cause fatigue and all are testable.

Gallbladder Symptoms

Gallstones are a labeled concern across this class, and rapid weight loss is independently a well-established risk factor for gallstone formation — meaning both the medication and the weight loss it produces point the same direction.

Labeled cholelithiasis (gallstone) rates:

These are low absolute numbers. They matter because the symptoms are distinctive and easy to dismiss as “just the medication”: pain in the upper right abdomen or just below the breastbone, often coming on after a fatty meal, sometimes radiating to the right shoulder blade, frequently with nausea. Pain that is severe, lasts more than a few hours, or comes with fever, chills, or yellowing of the skin or eyes needs urgent evaluation.

Related: how gallbladder risk is screened before and during treatment.

Sulfur Burps, Reflux, and Delayed Stomach Emptying

Sulfur burps — belching with a distinct rotten-egg smell — are a frequent and genuinely unpleasant complaint. Eructation is labeled at 7% for Wegovy 2.4 mg versus under 1% on placebo, 4–5% for Zepbound versus 1%, and 6–8% for Foundayo versus 1%. The plausible explanation is slowed gastric emptying leaving food in the stomach longer, allowing sulfur-containing compounds to form. Patients often find that temporarily reducing high-sulfur foods (eggs, red meat, cruciferous vegetables, some protein powders), eating smaller portions, and eating more slowly helps.

Reflux is labeled at 5% versus 3% for Wegovy and 4–5% versus 2% for Zepbound. Smaller meals, not lying down after eating, and avoiding large late-evening meals are the first steps.

Delayed gastric emptying itself is a labeled property of these drugs, not a rare event. Two consequences follow: the labels state these medications are not recommended in patients with severe gastroparesis, and absorption of other oral medications can change — the subject of the next section.

There is also a labeled precaution about pulmonary aspiration during general anesthesia or deep sedation. Before any procedure requiring sedation — surgery, colonoscopy, endoscopy, some dental work — tell the anesthesia team you are on a GLP-1. Current multisociety guidance risk-stratifies rather than telling everyone to stop, and protocols differ between hospitals, so have this conversation in advance rather than on the morning of the procedure.

Effects on Your Other Medications — Including Birth Control

This is the section patients have most often never heard, and the one with the highest stakes.

Delayed gastric emptying can change how other oral medications are absorbed. The Wegovy label advises considering increased clinical or laboratory monitoring when used with oral medications that have a narrow therapeutic index or require monitoring — thyroid hormone, warfarin, and some seizure medications and immunosuppressants are the usual examples. This is why your clinician should have your full medication list, including supplements.

The tirzepatide oral contraceptive interaction is the one that genuinely surprises people. The Zepbound prescribing information (rev. 4/2026) states:

“Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation.”

Read that ending carefully. Not just at the start — for four weeks after every dose increase. On a standard escalation schedule that is a repeating instruction over many months, yet it is frequently reported as though it were a one-time precaution at initiation.

Two clarifications matter:

• This instruction is specific to tirzepatide. The semaglutide labels carry no oral contraceptive interaction statement. Do not assume the two drugs behave identically here.
• All medications approved for chronic weight management are contraindicated in pregnancy, and current guidance advises stopping at least two months before a planned pregnancy. That makes reliable contraception during treatment a substantive issue, not a footnote.

If you take an oral contraceptive and are on or considering tirzepatide, raise this specifically at your next visit.

Alcohol: What Is Reported Versus What Is Established

Many patients say alcohol simply appeals to them less, or that a smaller amount affects them more than it used to. This is among the most frequently reported experiences on GLP-1s and among the least settled scientifically, so precision matters.

Reduced alcohol craving and consumption has genuine supporting evidence, but it is early. A Phase 2 randomized trial of low-dose semaglutide in 48 non-treatment-seeking adults with alcohol use disorder found reductions in laboratory alcohol self-administration, drinks per drinking day, and craving over nine weeks (Hendershot et al., JAMA Psychiatry, 2025). A 2025 systematic review pooled 14 studies and reported reduced alcohol intake, but its authors noted considerable heterogeneity, reliance on self-report, and that most evidence came from observational studies at moderate-to-serious risk of bias — concluding findings “should be interpreted with caution until substantiated by additional trials.”

Changed alcohol tolerance — feeling drunk faster or more ill afterward — is widely reported by patients but is not an established, quantified effect in the prescribing information. It is biologically plausible given altered gastric emptying and reduced food intake, but plausible is not demonstrated. Treat it as something to be cautious about, not as an established pharmacologic finding.

No GLP-1 is FDA approved for alcohol use disorder.

A Note on Mood, and a Correction Worth Making

On January 13, 2026 (updated April 3, 2026), FDA requested removal of the suicidal behavior and ideation warning from Saxenda, Wegovy, and Zepbound, citing a meta-analysis of 91 placebo-controlled trials covering 107,910 patients and a retrospective cohort of 2.2 million GLP-1 users. FDA’s heading read: “FDA’s Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of GLP-1 RA Medications.” A great deal of content online still describes that warning as current labeling. It is not.

A labeling change is not a claim that no individual ever experiences a mood change. If your mood, anxiety, or motivation shifts noticeably after starting or increasing a GLP-1, that is still worth telling your clinician.

Related: what FDA safety data actually shows.

Which Effects Improve With Time, and Which Do Not

Why Dose Escalation Pacing Matters More Than the Final Number

Most of the tolerable-versus-intolerable difference comes down to how fast the dose goes up. Label escalation schedules set a minimum interval — the Wegovy 7.2 mg label specifies tolerating 2.4 mg for at least four weeks before escalating — they are not deadlines to hit.

The 2026 ADA Standards of Care adds an under-reported point: the individualized maintenance dose should balance efficacy, health benefits, and tolerability, and “may not necessarily be the maximum approved dose” (Recommendation 2.16, graded A). If a lower dose is producing sustained results and you feel well on it, that is a legitimate destination — not a compromise.

When to Talk to Your Doctor

Routine — bring it up at your next visit or send a message:

• Constipation, sulfur burps, or reflux that is bothersome but manageable
• Hair shedding
• Taste changes making it hard to eat enough protein
• Mild fatigue
• Skin sensation changes that are mild and not worsening
• Any new mood change
• Starting, stopping, or changing any other medication or supplement
• An upcoming procedure involving sedation or anesthesia

Contact your clinician promptly (same day):

• Vomiting that will not stop, or an inability to keep fluids down — dehydration on these medications can cause acute kidney injury
• Pain in the upper right abdomen, especially after fatty meals, or with fever, chills, or yellowing of the skin or eyes
• Signs of low blood sugar if you also take insulin or a sulfonylurea
• New or worsening numbness, weakness, or severe skin pain

Seek emergency care:

• Severe, persistent abdominal pain, which may radiate to the back, with or without nausea or vomiting. This is how the labels describe possible acute pancreatitis, and it needs immediate evaluation.
• Signs of a serious allergic reaction: swelling of the face, lips, tongue, or throat; difficulty breathing or swallowing; severe rash or hives; rapid heartbeat with lightheadedness.

One thing this article is not: a reason to stop or change a prescribed medication on your own. Stopping abruptly, adjusting your own dose, or skipping doses to manage a side effect can create new problems. Every decision here belongs in a conversation with the clinician managing your treatment.

Scale Solutions & Coastal Georgia

Side-effect management is where an ongoing relationship with a clinician does the most work, because nearly every good decision here depends on context a single visit cannot supply.

Whether dysesthesia calls for holding a dose or stepping back depends on where you are in escalation and how you handled previous increases. Whether fatigue is under-eating, anemia, thyroid disease, or sleep apnea depends on your history and your labs. Whether upper-abdominal pain is reflux or a gallbladder needing imaging depends on someone taking a proper history — and, if imaging is needed, knowing where to send you locally and getting it done quickly.

That is the practical case for continuity of care: the same clinician tracking the same patient over time, with your full medication list in front of them and the ability to see you when something changes rather than after it resolves.

Scale Solutions is a physician-led practice serving Savannah, Chatham County, Pooler, Richmond Hill, Hinesville, and the surrounding Coastal Georgia communities. If you are on a GLP-1 and something has come up that you were not expecting — or you are about to start one and want a clear picture first — you are welcome to reach out. Bring your questions, and bring your medication list.

Related: the side effects most people are told about.

Related: what pancreatitis risk actually looks like.

Related: protein and muscle preservation during weight loss.

Related: eating well on semaglutide in Savannah.

Related: GLP-1s and alcohol.

Related: alcohol cravings and liver health on GLP-1s.

Related: how dose and response are monitored over time.

Related: standard semaglutide dose escalation schedule.

Frequently Asked Questions

Are there GLP-1 side effects doctors don’t tell you about? Not in the sense of anything being concealed — every effect discussed here is in the FDA prescribing information, which is public. What happens is more ordinary: appointments are short, the list is long, and clinicians lead with the effects most likely to be dangerous or to stop treatment. Less dramatic ones go unmentioned. Asking directly — “what else might I notice?” — is a useful question at any visit.

Why does my skin feel like it’s burning or tingling on semaglutide? That is likely dysesthesia, an altered skin sensation listed in the Wegovy prescribing information. It occurred in 22% of patients on 7.2 mg, 6% on 2.4 mg, and 0.3% on placebo, rising with dose and blood drug level. FDA notes it generally resolved on its own or with dose reduction. Report it to your clinician, and have any new numbness or weakness evaluated rather than assumed to be the medication.

Is hair loss from GLP-1 medications permanent? Typically not. The usual pattern is telogen effluvium — temporary shedding triggered by rapid weight loss — which generally resolves once weight stabilizes. Check protein intake and screen for iron, vitamin D, and thyroid problems, since those cause hair loss independently. Shedding that is patchy, severe, or continues after weight stabilizes should be evaluated.

Does Zepbound affect birth control pills? Yes. The Zepbound label advises patients on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting tirzepatide and for four weeks after each dose escalation — not just once at the beginning. The semaglutide labels do not carry this instruction. All medications approved for chronic weight management are contraindicated in pregnancy, so this deserves a specific conversation with your prescriber.

How do I stop sulfur burps on a GLP-1? There is no labeled treatment; the common approach is dietary — temporarily reducing high-sulfur foods such as eggs, red meat, cruciferous vegetables, and some protein powders, with smaller portions eaten more slowly. The underlying cause is thought to be slowed stomach emptying. Burping with severe pain, persistent vomiting, or an inability to keep food down is a different problem and needs evaluation.

Do GLP-1 side effects go away? Many do. Nausea often improves in the weeks after each increase; constipation, reflux, and burping respond to practical measures; dysesthesia is dose-related and often resolves on its own or with a reduction; hair shedding stops once weight stabilizes. A smaller group — severe abdominal pain, right-upper-abdominal pain, persistent vomiting, allergic reactions — are not things to wait out.

Should I stop my medication if I get side effects? That decision belongs with the clinician managing your treatment, not an article. Many side effects are handled by slowing escalation, holding at a dose, or reducing it rather than stopping. The 2026 ADA Standards of Care notes an effective maintenance dose “may not necessarily be the maximum approved dose.” What matters is telling someone what you are experiencing rather than quietly stopping.

Is it true GLP-1s make alcohol less appealing? Many patients report this, and there is early supporting evidence — a small randomized trial of low-dose semaglutide and a 2025 meta-analysis both found reduced alcohol consumption. But trial evidence is limited in size and duration, much of the supporting data is observational, and the review’s authors urged caution pending further trials. Feeling intoxicated faster is commonly reported but is not an established labeled effect. No GLP-1 is FDA approved for alcohol use disorder.

Conclusion

The side effects that catch people off guard are not the most dangerous ones — they are the ones nobody mentioned. Altered skin sensation, constipation, hair shedding, fatigue from under-eating, sulfur burps, and a birth control instruction that repeats at every dose increase are all documented, mostly manageable, and considerably less unsettling once you know they exist. The genuinely urgent symptoms are a short, specific list, and knowing which is which is most of the value of a page like this.

If you are in Savannah or anywhere across Coastal Georgia and something about your GLP-1 treatment has surprised you — a symptom nobody warned you about, a side effect that is not settling, or a question about whether your dose is escalating too quickly — Scale Solutions is happy to help you sort it out. Reach out anytime; no one should be guessing about this on their own.

MEDICAL SOURCES & FURTHER READING

FDA prescribing information

1. WEGOVY (semaglutide) injection and tablets — Prescribing Information, rev. 06/2026. Novo Nordisk. Dysesthesia rates (22% / 6% / 0.3%; tablets ~5%); adverse reaction table (nausea 44%, constipation 24%, eructation 7%, GERD 5%, fatigue 11%, hair loss 3%, dizziness 8%); cholelithiasis 1.6% injection / 2.5% tablets; §5.2 acute pancreatitis symptom description; §5.6 severe GI reactions and severe gastroparesis; §5.10 pulmonary aspiration; §7 drug interactions and delayed gastric emptying; dysgeusia 1.7% vs 0.5%. https://www.novo-pi.com/wegovy.pdf
2. ZEPBOUND (tirzepatide) injection — Prescribing Information, rev. 4/2026. Eli Lilly. §7.2 oral hormonal contraceptive instruction (verbatim quotation above); adverse reaction rates for constipation, hair loss, fatigue, eructation, GERD; cholelithiasis 1.1% vs 1%. https://pi.lilly.com/us/zepbound-uspi.pdf
3. FOUNDAYO (orforglipron) tablets — Prescribing Information, rev. 7/2026. Eli Lilly, via DailyMed. Constipation 20–27% vs 9%; hair loss 4–5% vs 2%; eructation 6–8% vs 1%; cholelithiasis 1.0% vs 0.7%. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
4. FDA Drug Safety Communication: FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 Receptor Agonist Medications. January 13, 2026; updated April 3, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp

Clinical guidelines

5. Gudzune KA, et al.; American Diabetes Association Professional Practice Committee for Obesity. Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. Published January 13, 2026. DOI 10.2337/doci25-0008. Recommendations 2.16, 2.19, 2.20; protein targets (minimum 60 g/day; 1.2–1.6 g/kg/day during weight reduction). Free full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC12815056/

Peer-reviewed literature

6. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395–405. doi:10.1001/jamapsychiatry.2024.4789. Phase 2, n=48, 9 weeks, low doses, non-treatment-seeking participants. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811
7. Eshraghi R, et al. Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis. eClinicalMedicine. 2025;90:103645. doi:10.1016/j.eclinm.2025.103645. 14 studies; authors note substantial heterogeneity and moderate-to-serious risk of bias in observational data.

Manufacturer medical information

8. Eli Lilly Medical Information — “What is the incidence of hair loss with Foundayo (orforglipron)?” Sex-stratified rates and the statement that hair loss events were associated with weight reduction. https://medical.lilly.com/us/products/answers/what-is-the-incidence-of-hair-loss-with-foundayo-orforglipron-317315

Editorial standards for Scale Solutions medical content: https://scale-solutions.com/editorial-policy/